U.S. Multiple Myeloma Market

Table of Contents

1 EXECUTIVE SUMMARY

• Executive Summary
  • Executive Summary

2 MARKET INTRODUCTION

• Research Scope and Methodology
  • Scope and Segmentation
  • Research Methodology
• Blood Cancer Overview
  • Blood Cancer Biology
  • Blood Cancer Definitions
• Multiple Myeloma Overview
  • Etiology
  • Staging and Prognostic Factors
  • Treatment Overview
• Patient Forecasts
  • Prevalence
  • Incidence
  • Mortality
  • Staging
• General Market Trends
  • Industry Challenges and Strategies
  • Market Drivers

3 PRODUCT AND PIPELINE ANALYSIS

• Approved Product Analysis
  • Chemotherapy Product Analysis
  • Steroid Product Analysis
  • Interferon Product Analysis
  • Immunomodulatory Product Analysis
• Pipeline Analysis
  • Chemotherapy Pipeline Analysis
  • Targeted Therapy Late Stage Pipeline Analysis
  • Targeted Therapy Early Stage Pipeline Analysis
  • Supportive Product Pipeline

4 COMPETITIVE ANALYSIS

• Introduction
  • Treatment Trends
  • Market Engineering Measurements
  • Common Drug Regimens
  • Drug Prices
• Market Revenue Forecasts
  • Total Market Revenue Forecasts
  • First-line HSCT Eligible Revenue Forecasts
  • First-line HSCT Non-Eligible Revenue Forecasts
  • Second-line Revenue Forecasts
  • Third-line+ Revenue Forecasts
  • Market Share Analysis
• Product Revenue Forecasts
  • Alkeran
  • Doxil
  • Revlimid
  • Thalomid
  • Velcade
  • Tanespimycin
  • ZIO-101
  • Perifosine

5 APPENDIX

• Decision Support Databases
  • Physicians
  • Government Healthcare Expenditure
  • Private Healthcare Expenditure
  • Pharmaceutical R&D Expenditure
  • Percent Pharmaceutical R&D Expenditure